Loading
HLX22 is an experimental monoclonal antibody from Shanghai Henlius Biotech in phase 3 trials for gastric & gastro-oesophageal junction cancer and HR-positive / HER2-negative breast cancer, aimed at HER2.
HLX22 is a monoclonal antibody developed by Shanghai Henlius Biotech. Its target is HER2 (the sponsor names HER2). The sponsor states: HLX22 is a recombinant humanised anti-HER2 monoclonal antibody injection, given at 15 mg/kg every three weeks in combination with trastuzumab and chemotherapy (XELOX) in HER2-positive gastric or gastroesophageal junction adenocarcinoma. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT06532006 (A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer), in gastric & gastro-oesophageal junction cancer and HR-positive / HER2-negative breast cancer. The largest, NCT06532006, plans to enrol 550 participants with primary completion expected 2027-06-01. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
HLX22 is a recombinant humanised anti-HER2 monoclonal antibody injection, given at 15 mg/kg every three weeks in combination with trastuzumab and chemotherapy (XELOX) in HER2-positive gastric or gastroesophageal junction adenocarcinoma. Connects to HER2.
1.HLX22 binds HER2.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"HLX22" OR ABSTRACT:"HLX22") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about HLX22, not a curated reading list.
Shares Shanghai Henlius Biotech, HER2, HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares HER2, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares Shanghai Henlius Biotech and the tag pipeline.
Shares Shanghai Henlius Biotech and the tag pipeline.
Shares Shanghai Henlius Biotech and the tag pipeline.
Shares Shanghai Henlius Biotech and the tag pipeline.
Shares Shanghai Henlius Biotech and the tag pipeline.
Shares Shanghai Henlius Biotech and the tag pipeline.